AstraZeneca Buys Into COVID-19 Antibodies From Newly Launched RQ Bio

Spin-Out From UK’s Antibody Taskforce

 
• By Andrew McConaghie
  
AstraZeneca Cambridge
Following its COVID-19 success, AstraZeneca has created a new division to commercialize vaccines and antibody therapies. • Source: AstraZeneca
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business